Lupus Pipeline Could See Momentum Following Two New US Approvals
Lupus Therapeutics Sees Improved Outlook For Challenging Area Of Drug Development
Executive Summary
Albert Roy, executive director of the clinical research arm of the Lupus Research Alliance, talked to Scrip about the outlook for lupus drug development.
You may also be interested in...
Bristol Confident To Move Deucravacitinib Into Phase III Lupus Trial
A Phase II study testing the TYK2 inhibitor in systemic lupus erythematosus met the primary endpoint. CMO Samit Hirawat talked to Scrip about the data and future development.
First-In-Class Drugs Made Up More Than Half Of US FDA’s Novel Approvals Last Year
CDER hit a high mark with 27 first-in-class approvals in the 50 novel agents cleared in 2021.
AstraZeneca To Challenge GSK After Clinching Lupus Drug Approval
Fears that US regulators would take issue with AstraZeneca's decision to change the endpoints of a second pivotal trial for anifrolumab were unfounded and the first-in-class type I interferon inhibitor is the first new treatment for systemic lupus erythematosus in more than 10 years.